NCT06388031View on ClinicalTrials.gov

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 9, 2024

Primary Completion Date

January 10, 2027

Study Completion Date

December 10, 2027

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Immune checkpoint inhibitor

"Physician's choice immunotherapy with one of the following every 21 days until disease progression or intolerable toxicity or up to 17 cycles:~* Pembrolizumab 200mg;~* Tislelizumab 200mg;~* Camrelizumab 200mg;~* Toripalimab 240mg."

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER